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Résumé
Les organogels présentent un grand intérêt en pharmacie galénique en raison de leur
facilité de préparation ainsi que leur capacité de libérer un principe actif de façon
prolongée. Dans le cadre de ce projet, un organogel a été évalué comme implant
injectable pour la libération soutenue de la rivastigmine, un inhibiteur de la
cholinestérase utilisé pour le traitement de la maladie d’Alzheimer. Le gel a été préparé
en dissolvant 5 — 15% (p/p) de N-lauroyle L-alanine methyl ester (SAM) dans l’huile de
carthame contenant la rivastigmine dissoute ou son sel d’hydrogène tartrate dispersé.
Les mesures de températures de transition, obtenues par calorimétrie différentielle à
balayage et par spectroscopie infrarouge, ont indiqué un affaiblissement de la structure
de l’organogel suite à l’incorporation de drogue dissoute (4% p/p). À la même
concentration, aucune modification en terme de température de transition n’a été
détectée dans les gels contenant le principe actif sous forme sel, indiquant une
interférence négligeable avec la matrice gélifiante. Ces mêmes gels ont démontré des
profils de libération in vitro ayant le plus faible effet « burst », avec moins de 15% du
principe actif libéré durant la première journée. Des études pharmacocinétiques réalisées
avec des rats ayant reçu par la voie sous-cutanée des organogels 10% SAM ont mis en
évidence une libération maintenant des concentrations plasmatiques de rivastigmine
dans la fenêtre thérapeutique pendant 11 jours. De plus, cette formulation a permis une
réduction de la concentration plasmatique maximale d’un facteur de 5 par rapport à la
formulation contrôle constituée d’huile sans gélateur. En conclusion, ce projet a
démontré la possibilité d’utiliser les organogels de SAM en tant que formulation à
libération prolongée pour le traitement de la maladie d’Alzheimer.
VMots clés: organogel, libération prolongée, implant autoformant in situ, rivastigmine,
maladie d’Alzheimer.
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Abstract
Organogels are interesting systems holding great promise for drug delivery applications
owing to their ease of preparation and potential for long-term release. This project
investigated the use of such an organogel as an injectable implant for the sustained
release of rivastigmine, a cholinesterase inhibitor used in the treatment of Alzheimer’s
disease. Such a formulation is expected to provide a simplified dosing schedule and
potentially reduce side effects associated to plasma peak concentrations. The gel was
prepared by dissolving 5 - 15% (w/w) N-stearoyl L-alanine methyl ester (SAM) in
safflower oil containing either dissolved rivastigmine or its dispersed hydrogen tartrate
sait. Differential scanning calorimetry and infrared spectroscopy indicated a weakening
of the oleogel structure by the incorporation of dissolved drug (4% w/w), as proven by
decreasing gel-sol transition temperatures. At the same concentration, no such changes
were detected for gels containing the dispersed drug salt, indicating negligible
interference of the latter with gel auto-assembly. In vitro release profiles of gels
containing dispersed rivastigmine showed the lowest burst (<15% in the first day). A
pharmacokinetic study, in which rats were injected subcutaneously with 10% SAM gels
containing the dispersed drug, demonstrated a sustained rivastigmine release within
therapeutic range for up to 11 days. Peak plasma levels were found to be well below the
toxic threshold and up to five times lower than for the control oil formulation. Overall
this project established SAM gels to be a promising option for a sustained-release
formulation in the treatment ofAlzheimer’s disease.
Keywords: organogel, sustained release, in situ-forming implant, rivastigmine,
Alzheimer’s disease.
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CHAPTER 1
Alzheimer’s disease
21. Introduction
Alzheimer’s disease (AD) is the most common form of dementia amongst elderly and is
estimated to afflict 1$ million people worldwide [1]. With an increasingly aging
population, the prevalence of AD is on the rise. The disease takes an enormous toll on
society, both at financial and social levels. Indeed, about $100 billion dollars in caring
costs are spent annually in the United States alone. Meanwhile, with around 70% of
patients living at home, great physical and emotional stress is placed on caregivers [1].
AD is a progressive neurotogical condition, evolving from short-term memory
impairment to profound cognitive disturbances (such as severe memory loss, leaming
difficulty, and language disorder), behavioural disturbances (such as aggression,
depression, and wandering), as well as physical disability [2]. After diagnostic, patients
usually survive 7 to 10 years, and typically die from bronchitis or pneumonia [3].
2. Pathophysiology
The disease is characterized, as determined from autopsies, by the extracellular
deposition of f3-amyloid protein in senile plaques and the intracellular formation of
neurofibrillary tangles. The process is thought to be initiated by the production and
accumulation of the neurotoxic 13-amyloid peptide, the main component of 3-amyloid
plaques. This leads to the formation of neurofibrillary tangles, oxidation, glutametergic
excitotoxicity, inflammation, and finally an activation of neuronal apoptosis (Figure 1)
[4].
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Figure 1: The hypothesis of the amyloid cascade proposes a progression from the
generation of 3-amy1oid precursor protein (APP), through multiple secondary steps, to
ceil death. Reproduced from reference [4].
43. Treatment options
The celi dysfunction and death brought about in several neurotransmitter systems lead to
deficits in acetylcholine, norepinephrine, and serotonin. This hypothesis underlies
current pharmacological approaches to the disease (Table I). Amongst these, two
classes of drugs are presently on the market, targeting the cholinergic and glutamate
systems, respectively. Cholinesterase inhibitors (ChEI) increase acetylchoÏine levels at
synapses by preventing its breakdown, thus prolonging neurotransmission in remaining
cholinergic neurons [5j, while N-methyl-D-aspartate (NMDA) antagonists are believed
to work by regulating levels of glutamate in the central nervous system.
3.1. Cholinesterase inhibitors
Since 1997, three second-generation ChEI have been approved by the food and Drug
Administration (fDA) for treatment of mild to moderate AD: donepezil, rivastigmine,
and galantamine (Table I). These agents are currently the first une of symptomatic
treatment. Clinical trials have suggested that ChEI may help improve cognitive ability
of AD patients. Nevertheless, the overati efficacy of these drugs is generally considered
to be modest [4]. Similarly, their slowing of disease progression is controversial [1].
ChEI drugs are generally well tolerated, with possible side-effects of gastrointestinal
nature, such as nausea and anorexia. While the three active agents have similar efficacy
and tolerability profiles, rivastigmine is the only marketed ChEI that has its effect
targeted on the cortex and hippocampus, the areas most affected by the disease.
5Table I: Current drugs on the market or in clinical trials for the treatment of AD;
adapted from reference jlJ.
Drug Company Mechanism Status
donepezil approved for mild -EisaiiPfizer ChEI(Aricept) moderate AD
rivastigmine approved for mild -Novartis ChEJ(Exelon ) moderate AD
galantamine approved for mild -
® Johnson & Johnson ChEI(Reminyl /Razadyne ) moderate AD
memantine approved for moderate -Lundbeck/Forest NMDA receptor antagonist(Namenda IEbixa ) severe AD
tramiprosate
(Alzhemed®) Neurochem amyloid plaque inhibition Phase 3
R-fiurbiprofen NSAID’ lowers j3-amyloidMyriad Genetics Phase 3(Flurizan ) levels
leuprolide acetate Voyager Implantable leuprolide Phase 3(Mernryte ) Pharmaceuticals
neramexane Merz & Co NMDA receptor antagonist Phase 3
xaliproden Sanofi-Aventis 5-HT la agonist Phase 3
lecozotan Wyeth 5-HT la agonist Phase 3
Targacept/ nicotinic acetylcholineispronicline Phase 2AstraZeneca agonist
3-amyloid-speciflcbapineuzumab Wyeth/Elan Phase 2
monoclonal antibody
‘NSAID: non-steroidal anti-inflammatory drugs
Also, as opposed to donepezil and galantamine. rivastigmine presents a tow risk for
tolerance caused by enzyme induction and/or upregulation. Likewise, it shows a very
low potential for drug-drug interactions and accumulation in the body, even with long
term use [6]. Nevertheless, donepezil, the first second-generation Chu to enter the
6market, has remained the leading product in its class. Antioxidants such as vitamin E are
often recommended in conjunction with ChEI up into the late stages of the disease, but
this practice is controversial due to the Yack of supporting clinical data [1].
3.2. Other therapies
While ChEI are only recommended up to moderate disease stages and have littie or no
impact on disease progression, the NMDA antagonist memantine, approved by the FDA
in 2003, has transformed the treatment of moderate to severe AD. This active agent is
thought to interfere with glutamergic excitotoxicity and provide symptomatic
improvement through effects on the function of hippocampal neurons [4]. Clinical trials
have shown an improvement in cognitive function of memantine- over placebo-treated
patients, although as for the other current therapies, improvements remain modest [4].
The potential for combination therapy has been explored, and whiÏe some studies have
shown encouraging preliminary data, suggesting that treatment with memantine in
addition to donepezil is superior to donepezil alone [7], others have concluded that no
significant improvement was achieved [8].
While current therapies show modest symptomatic improvements in AD patients, the
underlying degeneration of brain celis and consequent disease progression generally
remain unaffected by these therapies. Consequently, ongoing research and clinical trials
explore new treatment hypotheses (Table I). Several of these agents are aimed at
countering amyloid plaque deposition, formation of neurofibrillary tangles, and
neuroinflammation. It is argued that the most promising of these avenues is the targeting
of the 3—amyloid peptide [1]. The most advanced drug in this class is tramiprosate,
7which binds soluble 3—amyloid, preventing its aggregation into amyloid plaques.
Clinical trials revealed the compound to be of moderate efflcacy in reducing f3—amyloid
plaques [9,10]. Another interesting pharmacological approach is represented by
bapineuzumab, a humanized monoclonal antibody against 3—amyloid, currently studied
in Phase 2 trials. Immunotherapy leaves room for hope of a truly disease-modifying
approach; however it also entails the greatest risks. Earlier drug candidates have caused
cases of encephalitis [1]. It remains to be seen if any of the drugs currently under
investigation will provide disease-modifying mechanisms and be safe enough for market
release.
Given current pharmacological options for AD patients, a possible way of facilitating
disease management could be the administration of sustained release formulations. One
example such example bas been the commercialization of the oral once-daily
formulation of galantamine (Razadyne®), an improvement over the previous twice-daily
regimen. Simplified dosing schedules could possibly entail increased treatment
adherence and compliance, while alleviating responsibility and workload for caregivers.
Peak and trough plasma concentrations of the active agent are also potentially
minimized, which can decrease side effects.
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CHAPTER 2
Snstained release systems
rn
Parenteral sustained release systems act as reservoirs for the incorporated active agent,
releasing the latter over time spans ranging between hours and months. These systems are
generally administered via the peritoneal, subcutaneous, or intramuscular routes, and can
be used for systemic or local treatment.
Sustained release systems gained popularity since the early eighties when the first
polymeric implants were commercialized for the delivery of goserelin (Zoladex®) and
levonorgestrel (Norplant®), for prostate cancer treatment and contraception, respectively
[1]. Microspheres have been developed shortly afier for sustained release applications.
These systems are constituted of polymeric particles, most commonly polyesters such as
poly(lactic acid) (PLA) and poly(lactic acid-co-glycolic acid) (PLGA), which are injected
subcutaneously or intramuscularly. Microsphere depot formulations containing leuprolide
(Lupron®) were extensively studied t21 and finally marketed for the long-term release of
the active agent with a consequent suppression of testosterone for up to 6 months. A
number of studies have investigated the encapsulation of ChEI into biodegradable
microspheres of PLA and PLGA [3-6]. These studies showed the potential of drug
delivery over prolonged periods. Unfortunately, neither of the model drugs used
(huperzine A and tacrine) is commonly used in AD management due to lack of FDA
approval and hepatic toxicity, respectively.
Overall, microsphere systems are interesting since many are recognized as being
biodegradable and biocompatible [7]. However, important shortcomings of these systems
limit their use in drug delivery, notably the complexity of preparation for stable and
‘I
sterile formulations and the potential degradation of the active agent during this process.
The possibility of microsphere migration away from the injection site can be of nuisance
when local treatment is needed. More importantly yet, the formulation cannot be removed
in the case of toxic effects following administration. Accordingly, in recent years, such
systems have yielded the spotlight to in situ-forming systems allowing sustained drug
release.
In situ-forming implants are liquid systems which solidify upon injection, as a resuit of
changes in temperature and/or pH, or solvent diffusion [1]. Based on the specific
solidification mechanisms, various categories of implants exist, notably thermoplastic
pastes, precipitated polymers, hydrogels, and organogels. Each system will be briefly
discussed in this section, while organogels will be presented in detail in Chapter 3.
Thermoplastic pastes are composed of polymers which are injected in the molten state
and solidify upon injection as a result of temperature drop. These polymers have a
melting point between 25 and 65°C and a glass transition temperature below the
physiological temperature [8,9]. The latter characteristic is important since the system’s
viscosity has to present a compromise; while being high enough to provide an adequate
rate of release, it must be low enough to permit easy injection through conventional
needles [9]. Typical polymers used are composed of lactic and glycolic acids, E
caprolactone, and orthoesters. Poly(ethylene oxide) (PEO) and albumin can be
incorporated to provide accelerated release of the active agent. The inherent disadvantage
of these systems is the relatively high temperature at which they must be injected. This
12
can trigger pain and possible necrosis at the administration site. The consequent
formation of fibrous tissue around the implant may lead to erratic or insufficient release.
In situ-forming systems can also be produced by chemical or physical crosslinking of
polymer chains, yielding solid three-dimensional matrices capable of offering a delaying
effect on drug release. The main concem with such systems is the high burst release upon
injection, produced by the delay in implant solidification [10]. This is greatly limiting for
long-term sustained release applications. Also, polymer crosslinking subsequent to drug
incorporation to the formulation involves the risk of chemical modification of the latter
and ensuing loss oftherapeutic efficacy. Certain formulations have been developed which
circumvent this problem, as is the case of a thiol-derivatized poly(ethylene oxide) system
which circumvents the need for radical polymerization by allowing crosslinking at the
thiol group via a linker [111. However, this formulation is not biodegradable. finally,
another important shortcoming of crosslinked polymer systems is the inherent toxicity of
initiators.
As a consequence to the problems associated with chemical crosslinking, polymeric
systems relying on solidification triggered by physical interactions seem to be a more
reasonable choice for pharmaceutical applications. These systems rely on hydrophobic
and/or electrostatic interactions to form the solid systems. The constituting block
copolymers contain hydrophilic and hydrophobic parts, which upon a play on
temperature and/or pH induce a solidification of the system as a resuit of altered
differential solubilities of the polymer moieties. for example, various such systems are
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soluble in cofd aqueous media but form a gel upon an increase in temperature. This
phenomenon is the resuit of dehydration of the hydrophobic chain. a consequent loss of
solubility in water, and a formation of colloidal systems such as micelles. If colloid
density exceeds a given threshold, typically encountered at polymer concentrations of 15-
23%, phase mixing occurs between the hydrophilic micelle coronas and the hydrophobic
cores, leading to chain entanglement and consequent gelation. [8]. Such polyrners most
commonly include poloxamers and ABA-type polymers with PEO as the hydrophilic (A)
and poly(propylene oxide) as the hydrophobic (B) moiety [12-14]. The major drawback
of these systems is the fast release of small hydrophilic molecules through the large
aqueous channels formed in the porous implant. furthermore, poloxamer gels are flot
biodegradable and have been found to cause metabolic changes in rats t15]. Other
thermosensitive di- and tri-bloc copolymers composed of PEO and PLA, PLGA. and/or
poly(E-caprolactone) have also been developed in efforts to transcend the problems
associated with poloxamer gels [16,17]. These systems were shown to provide adequate
release for model drugs, ranging from days to several weeks, for increasingly
hydrophobic molecules. A change in pH can also trigger the physicat crosslinking of
polymers [18,19]. Such systems are mostly used for oral formulations, given the high
variations in pi-I along the gastrointestinal tract.
Finally. the precipitation of compounds as a result of temperature changes or in response
to solvent diffusion is also a mechanism exploited for in situ-forming systems. An
example is Atrigel, composed of PLA, PLGA, or poly(lactic acid-co-E-caprolactone)
dissolved in N-methylpyrrolidone (NMP). Encouraging animal studies using this system
have lead to the commercialization of Eligard’, a formulation providing therapeutic
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plasma concentrations of leuprolide in humans for 3 to 6 months [20]. This constituted
the first in situ-forming implant approved for use in humans. SABER® is another system
ensuring sustained drug release following in silu-precipitation. This formulation is
composed of sucrose acetate iso-butyrate, a water-insoluble compound, dissolved in
ethanol at concentrations of 80-90% [21]. Injection of the low-viscosity system is
followed by solvent diffusion into sunounding tissue and formation of a solid implant
capable of providing sustained release of active agents, including proteins, for up to
several weeks [21,22].
Organogels, composed ofa liquid organic medium immobilized by gelling molecules, are
particularly interesting as a drug delivery platform, owing to the simplicity of their
preparation. These systems will be discussed in detail in chapter 3, while chapter 4 will
focus on the use of an organogel system for the sustained delivery of rivastigmine.
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CHAPTER 3
Organogels and their use in drug delivery — A review
1$
1. Abstract
Organogels are semi-solid systems, in which an organic Iiquid phase is immobitized by a
three-dirnensional network composed of self-assembled, intertwined gelator fibers.
Despite their majoritarily liquid composition, these systems demonstrate the appearance
and rheological behaviour of solids. Investigative research pertaining to organogels has
only picked up speed in the last few decades. Consequentty, rnany burning questions,
such as the specific molecular requirernents guaranteeing gelation, stiil await definite
answers. Nonetheless, the application of organogels to various areas of interest has been
quick to follow their discoveries. Unfortunately, their use in drug delivery is stili quite
limited by the scarce toxicology information available on organogelators, as well as by
the few pharmaceutically-accepted solvents used in gel systems. This review aims at
providing a global view of organogels, with special emphasis on the interplay between
the gelators structural characteristics and the ensuing intermolecular interactions. A
subsequent focus is placed on the application of organogels as drug delivery platforms
for active agent administration vici diverse routes such as transderrnal, oral, and
parenteral.
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2. Introduction
for the past few decades, gels have been presented. to the extent of a cliché, as being
materials “easier to recognize than define”, a prophetic statement pioneered in the
192OEs by Lloyd [1]. Various definitions have followed. sometimes a same author
providing descriptions ranging from the most elaborate, stating that a gel 1) bas a
continuous structure of macroscopic dimensions that are permanent over the time-span
of an experiment and 2) is solid-like in its rheological behaviour, to the more basic
descriptions stating that if it looks like Jell-O”, it must be a gel [2]. It is now generally
accepted that a gel is a semi-solid material composed of low concentrations (< 15%) of
gelator molecules that, in presence of an appropriate solvent, self-assemble via physical
or chemical interactions into an extensive mesh network preventing solvent ftow as a
result of surface tension. Gels have been eloquently described as being the result of
“crystallization gone awry [3]. Indeed, macroscopic phase separation into crystalline
and liquid layers is avoided in these systems owing to the balance between gelator
aggregating forces and solubilizing solvent-aggregate interactions. The result is a system
ofcrystallized fibers that immobilize the liquid phase.
The specific process leading to the formation of the gelling matrix depends on the
physicochemical properties of gel components and their resulting interactions. Figure I
presents a fiow-chart compiling various accepted classifications of gels based on the
nature of solvents, gelators, and intermolecular interactions.
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Organogels, the focus of this review, can be distinguished from hydrogels by their
predominanfly organic continuous phase and can then be further subdivided based on the
nature of the gelling molecule: polymeric or low molecular weight (LMW)
organogelators. Polymers immobilize the organic solvent by forming a network of either
cross-linked or entangled chains for chemical and physical gels, respectively. The latter
are possibly further stabilized by weak inter-chain interactions such as hydrogen
bonding. van der Waals forces, and it-stacking. Likewise, the self-assembly of LMW
organogelators depends on physical interactions for the formation of aggregates
sufficiently long to overlap and induce soïvent gelation. Depending on the kinetic
Figure 1: Organogel classification.
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properties of aggregates, an important distinction amongst LMW organogels is made
between those composed ofsolid (or strong) versus fluid (or weak) fiber networks.
Despite the numerous trends in gelling processes as well as the impressive variety of
gelators identified [4], it remains difficuit to predict the molecular structure of a
potentiat gelator, as well as one cannot readily foresee preferentially-gelled solvents.
Today stiil, the discovery of gelators rernains serendipitous and is usually followed by
investigative screening of different solvent systems potentiatly compatible with gelation.
Prediction of gelation potential of a given molecule might seem possible by
investigation of its propensity towards chemical or physical intermolecular interactions;
however, no generalisations are so far possible. Many factors such as steric effects,
rigidity, and polarity can counter the molecule’s aggregating tendency. Control over the
gelation process as well as the systematic conception of new gelling molecules remain
important challenges to face in the quest of new organogelators.
In the pharmaceutical field, organogels can be used for drug and vaccine delivery via
different administration routes, although relatively few such formulations have been
investigated [5]. This review aims in its flrst part at providing a global view of the
different existing organogelator categories while secondly providing a more focused
discussion oftheir drug delivery applications.
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3. Organogel properties
3.1. Low molecular weight organogelators
Amongst LMW organogels, a subtie but crucial distinction is made between those
composed of entangled networks of solid versus fluid fibers (figure 2) [3].
A) B)
Figure 2: Solid-matrix (strong) versus fluid-matrix (weak) organogels. A) Solid-matrix
gels are more robust due to their permanent solid-like networks in which the junction
points are relatively large (pseudo)crystalline microdomains (circled area). B) fluid
matrix gels have transient networks in which junctions points are most ofien simple
chain entanglements. Additional kinetic features such as dynamic exchange of gelator
molecules with the bulk liquid as well as chain breaking/recombination (arrows) may
occur. Adapted with permission from reference [3].
The solid fibers, out of which most organogels are composed, are generally produced
following a drop in temperature below the gelator’s solubility limit [61. Consequently, a
fast partial precipitation of gelator molecules in the organic medium resuits in the
formation of aggregates via cooperative intermolecular interactions (f igure 2A) [7]. On
the other hand, fluid matrices are formed upon the incorporation of polar solvents to
organic solutions of surfactants, which resuits in the reorganisation of surfactant
molecules into mono- or bilayer cylindrical aggregates that immobilize the solvent
(figure 23) [71. The key distinction between the two systems is the kinetic stability of
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the networks constituting the gel state. Strong gels are formed of permanent, most oflen
crystalline, networks in which junction points are relatively large (pseudo)crystalline
microdomains [3]. Conversely, weak gels are fonried of transient networks,
characterized by the continuous breaking and recombination of the constituent rods, as
in the case of reverse cylindrical micelles [8,9]. Similarly, aggregates undergo dynamic
exchange of individual gelator molecules with the bulk liquid. Junction points in these
fluid networks are simple chain entanglements, equally transient in nature.
The distinction between solid and fluid fibers is not much emphasized in the literature,
although it is of great importance from a physicochemical stand point. Solid-matrix gels
are more robust, as demonstrated by rheology studies [3]. This may be at least partially
due to the fact that, while fluid fibers do not aggregate into higher-order structures, solid
fibers are generally aligned in bundles as a result of their rigidity [7], likely conveying
added robustness to the gel. Similarly, while molecular and supramolecular chirality
plays a great role in the formation and stability of solid fibers, its effect is rare in fluid
networks [6,7].
3.1.1. Solid matrix organogels
The vast rnajority of LMW organogelators discovered so far self assemble into solid
networks when added to appropriate organic solvents.
3.1.1.1. Generat gelling considerations
In merely a century of organogel research, hundreds, if not thousands of LMW
molecules with gelling properties have been discovered, most ofien by chance rather
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than design. Several extensive reviews have been published on the topic in general [3,4],
as well as on more pointed discussions: fiber formation mechanisms [10] and gelator
families derived from various parent molecules such as fatty and amino acids [3],
organometallic compounds [3], steroids [3,11], amide- or urea compounds [12],
nucleotides [13], and dendrimers [14].
Solid-matrix gels are prepared by dissolving the gelator in the heated solvent, at
concentrations typicalÏy inferior to 15%. Very low concentrations of less than 0.1% have
been reported in the case of sugar-derived “supergelators” [15]. Upon cooling, the
afflnity between organogelator and solvent molecules decreases and the former self
assemble into solid aggregates held together by intermolecular physical interactions. The
remaining solvent-aggregate affinity stabilizes the system by preventing complete phase
separation. Aggregates are most often formed by the unidimentional growth into libers
with high aspect (length-to-width) ratios, generally measuring a few tens of nanometers
in width and up to several micrometers in length. One such example are L-alanine fatty
acid derivatives which form opaque gels in pharmaceutical oils as a result of hydrogen
bonding and van der Waals interactions [16,17] (Figure 3).
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Although less common, examples exist of two-dimensional growth pattems, as in the
case of hexatriacontane, a 36-carbon n-alkane (C36), which forms microplatelet
arrangements (figure 4).
C)
C
/
B)
Figure 4: A) optical micrograph of a (4%) hexatriacontane (C36) organogel in octanot
viewed through crossed polars; B) a cartoon representation of the microplatelets
observed in A); C) depiction of the lamellar orthorhombic molecular packing inside the
platelets, showing the directions of microplatetet growth. Adapted with permission from
reference [19].
Figure 3: A) Photograph depicting the opaque N-stearoyl-L-alanine methyl ester
organogel; B) optical micrograph showing the fibrous aggregates responsible for
gelation; C) molecular packing within fibers. Adapted with permission from [1$].
Piatelet
growth
directions
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Both one- and two-dirnentional aggregates are frequently crystalline in nature. The
crystalline arrangement can be the same in the gel and the neat solid, as in the case of
C36 molecules, of which the gel microplatelet arrangements are free of liquid molecules
in the interlamellar spaces [19]. However. more ofien than flot, the crystalline packing
differs between the gel and the neat solid [3]. Macroscopically, organogels range in
appearance ftom white opaque to translucent, likely depending on aggregate size and the
consequent gel’s abilïty to scatter incoming light. Sometimes, a sarne gel system can
change in its degree of transparency upon small variations in composition [201.
While hydrophobic attractions are a major driving force for gelator aggregation in water,
these interactions are of secondary importance in the case of organogels. In non-aqueous
liquids, the attractive forces are mainly hydrogen-bonding, van der Waals interactions,
rc-stacking. and metal-coordination bonds. Because of the strength and high
directionality of their hydrogen-bonds, numerous emerging organogelators are
derivatized peptides [4,12], sugars [15,21,22], and bis-urea-based compounds [12].
These are particularly eflicient organogelators because of their hydrogen-bonding core
that provides a gelling scaffold which can be functionalized for extended versatility.
Organogelators consisting of long n-alkanes (chain length varying from 24 to 36 carbon
atoms) have proven to be of particular interest in dernonstrating the mechanisms of
gelation [20]. They are not only rare examples in which hydrogen-bonding does not play
a role in gel formation, but are even more unusual in that van der Waals forces alone
lead to gelation. As a consequence of gelling solely through these weak physical
interactions, such gels are not stable over long periods, eventually phase-separating due
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to transitions towards thermodynamically-favoured packing arrangements. Not
surprisingly, it was noted that gel sheif-life increased with gelator chain length as a
resuit of extended van der Waals interactions, going from under a day to several months
for C24 and C36, respectively [20].
A recent study involving a family of 3.5-diarninobenzoate derivatives dernonstrated,
although flot for the first time, the implication and importance of aromatic stacking in
the process of gelation [23]. Indeed, increasingly stronger gels were formed upon
incorporation of additional aromatic substituents to gelator molecules. Another
interesting class of gelators involving Tt—7t interactions are cholesterol-derivatized
molecutes. These can be very suitable for the design of functionalized organogelators
because of their rernarkably high synthetic tunability [3.11]. The cholesterol group
induces uni-directional self-association though van der Waals interactions, while
functional groups added onto the cholesterol backbone stabilize the fiber via hydrogen
bonding and/or 7t-lt interactions. The hydroxyl group at the C3 position of the
cholesterol molecule is crucial to gelation, likely due to its participation in hydrogen
bonding [3]. Alternatively, steroids (S) derivatized at the C3 position with anthraquinone
(A) via a linker (L) of varying length (ALS compounds) are known to forrn stable
organogels. The fused aromatic rings of the anthraquinone group stabilize gel fibers by
7t-stacking.
2$
3.1.1.2. Chirality Effi?cts
Chirality is neither necessary nor sufficient for gelation; however, despite flot being a
gelling-force in itself, chirality seems to be intimately related to the growth and stability
of the self-assembled fibrillar networks of LMW physical gels [3]. While this section
strives at providing the reader with a general view of underlying principles of chirality
and their impact on gelation, more extensive information can be found in a recent and
excellent review by Brizard et al. [6].
Although the exact explanation remains yet to be formulated, a general empirical rule is
that a molecule has a better chance of being a good gelator if it is chiral. Indeed, a large
majority of existing organogelators possess at Ieast one stereogenic center, while non
chiral gelators are generally cited as being exceptions to the rule [6]. Furthermore, it can
be specified that chirality is only determinant in the case of solid fibers due to their
marked rigidity, while rarely being of effect in fluid fibers which are highly dynamic in
nature [7].
b further understand the stabilizing effect of chirality, it must first be said that it is
known to play important roles both at the scale of individual molecules as well as that of
resulting fibrillar aggregates. Indeed, molecular chirality is most ofien transferred to the
morphology of self-assembled fibers, as shown by numerous studied systems [24-2$].
One such example are crown ether phthalocyanine organogels, composed of supercoiled
helical fibers (Figure 5).
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Figure 5: A) Transmission electron rnicrograph of organogel of a crown ether
phthalocyanine in chloroform, showing a left-handed cou. B) Schematic representation
of helical fibers in A). C) The helical aggregates are fornied by the stacking of crown
ether rings with a staggering angle, constant in magnitude and direction. D) Supercoiled
structure is obtained from side-on aggregation of individual fibers. Reproduced with
permission from reference [27].
Initial molecular packing. driven by it-stacking between substituent aromatic rings,
transfers molecular chirality to individual fibers, which further twist around each other
into helical superstructures to maximize van der Waals interactions [27]. As opposed to
flat aggregates, the contact area between such twisted structures is reduced due to their
curvature. which makes them less prone to uncontrolled aggregation and to the resulting
precipitation. This increases the chance of gelation by such chiral molecules. The
opposite is generally true of racemic mixtures. These most often form flat aggregates
that are more prone to uncontrolled crystallization [24,29].
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N-stearoyl alanine methyl ester is an example of a compound showing superior gelling
abilities when enantiomerically pure. Such gels exhibited higher transition temperatures
than their racemic counterparts (Figure 6) [30].
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figure 6: A) Gelator chirality effect showing a decrease in DSC-determined sol-gel
(white bars) and gel-sol (solid bars) transitions in racemic organogels (N-stearoyl D/L
alanine methyl ester, D/L-SAM) with respect to enantiomerically-pure L- and D-SAM
organogels, respectively (mean, n = 2). B) FTIR analysis showing the proportion offree
gelator amide bonds in gel systems, as determined from the band intensity ratio of amide
I peaks at 1685 and 164$ cm’ (116x5/11648), as a function of temperature.
Enantiomerically pure L-SAM (.) organogels showed higher gel-sol transition
temperatures than D/L-SAM (E) organogels (mean + SD. n = 3) [30].
Meanwhile. racemic mixtures are often reported to form weaker gels, to crystallize [24],
or to precipitate as flakes or pellets [6]. Nevertheless, a few examples have been
reported in which racemates actually form stronger and/or more stable gels than their
enantiomerically pure analogues, demonstrating that although racemates are often poorer
L-SAM D-SAM O/L-SAM 10 20 30 40 50 60 70 80 90
Temperature (°C)
gelators. this empirical observation cannot be taken as a rule [6].
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3.1.2. f luid-matrix organogets
fluid fibers gel organic solvents in much the same way as solid fibers: aggregate size
increases and the eventual entanglement of these structures immobilizes the solvent as a
resuit of surface tension. Just as strong gels, fluid matrix systems are thermoreversible
and can be transparent or opaque. The critical difference arises in the kinetic behaviour
of the two types of matrices. Whule solid matrices have a robust and permanent
morphology over the gel’s lifespan, fiuid matrices are transient structures in constant
dynamic remodelling (figure 2) [3]. Owing to the aggregate fiuidity and the transience
ofjunction points, these structures are atso referred to as “worm-like” or “polymer-like”
networks. This section presents two such systems, lecithin and sorbitan monostearate
(SMS) (and/or sorbitan monopalmitate) organogels. which are both of very high interest
in pharmaceutical sciences.
3.1.2.1. Leciihin organogels
From a drug delivery standpoint, lecithin organogels (LO) are very interesting systems,
owing to their biocornpatibility, their amphiphilic nature, facilitating dissolution ofdrugs
of various classes, as well as their permeation enhancement properties. Lecithin, or
phosphatidylcholine (Table I), is the most abundant phospholipid in biological systems
and is typically extracted from soy beans and egg yolk. Due to its amphiphilic structure,
lecithin can assume many different forms such as mono- and bi-layer films. vesicles.
liquid crystals, emulsions, and organogels [9]. When mixed to organic solvents, lecithin
yields isotropic reverse-micellar solutions. Upon the addition of small amounts of polar
solvents, cytindrical reverse micelles start to grow until they entangle into a gelling
network (figure 7).
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Figure 7: formation of a three-dimensional network of reverse cylindrical micelles in
lecithin organogel, involving hydrogen bonding between lecithin and polar solvent
molecules. Adapted with permission from reference [31].
Despite having been termed “weak” organogels, LO present very high viscosities, in
several cases higher than that of gelatin [32]. Scartazzini et aÏ. [32] were the first to
report a systematic investigation of LO, their resuits subsequently conflrmed by several
groups. Indeed, evidence was presented suggesting that the rise in the systems’ viscosity
was due to the growth and overlap of reverse tubular micelles [33-35] and flot to any
form of liquid crystalline order [33]. as in the case ofbinary water-lecithin systems [9].
The hypothesis of entangled reverse micelles was proven by infrared spectroscopy
studies showing a low-frequency shift of the PO vibration band for lecithin molecules
upon gel formation, indicating the involvement of the phosphate group in H-bonding
with the added polar solvent [34,36]. No indications were found of interactions at the
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carbonyl groups and the glycerol residue of lecithin. Based on this evidence. a structural
model was proposed, in which the lecithin phosphate group and polar solvent molecules
are connected by H-bonds, thus forming a linear structure of alternating solvent and
lecithin molecules, which ultimately self-assembles into overlapping worm-like reverse-
micelles (Figure 7). Corroborating NMR studies [37-401 showed a une broadening for
phosphorous and hydrogen resonances of the polar head-group upon an increasing
molecular ratio of solvent-to-lecithin (w0). This suggested a progressive molecular
stiffening of this part of the molecule upon polar solvent addition, consistent with the
hypothesis ofinverted cylindrical micelle formation and entanglement.
Several polar solvents, many suitable for in vivo use, were found appropriate for
induction of gelation. Glycerol provided maximal viscosity of the temary system at the
lowest concentration (w0 = 1.7 - 1.9), followed by water (w0 = 3.6
- 3.8). formamide (w0
= 3.6 - 4.8), and ethylene glycol (w0> 5) [341. Other solvents such as ethyl alcohol and
diethylene glycol did flot induce organoget formation. In fact, it was suggested that the
difference between gel-forming and non-gel-forming solvents was their orientation and
localization between lecithin molecules, which in tum depended on their polarity [36].
Similariy, ail geiling-soivents were found to have a strong tendency towards hydrogen
bonding, with hydrogen-bond donating potential seeming to be more important than
hydrogen-bond acceptance. In terms of the hydrophobie organic solvents compatible
with gel formation, Scartazzini et al. [32] concluded that the more apolar solvents such
as alkanes, followed by cycloatkanes, allow a higher state of structural organization of
the lecithin molecules. thus forming more stable gels.
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Phase diagrams were obtained by severai groups, describing the variation of the lecithin
system viscosity with the addition of increasing amounts of polar solvent. They
rernained relatively constant for ail hydrocarbon solvents used [33,34,36] (figure g).
Organogel Two-phase
Reverse- f ‘i. system:
micellar / solution +
solutIon / gel Two-phase
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/ solution +
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Figure 8: PLot ofzero shear viscosity versus the water-to-lecithin molecular ratio (w).
Dotted unes roughly indicate boundaries between various phase regions. Adapted with
permission from reference [36].
Siight variations occurred for certain other organic solvents [41]. but the evoiution ofthe
lecithin system structure upon addition of polar solvent is a constant. The initial lecithin
reverse-micelle solution aiways presents a sharp increase in viscosity upon the addition
of criticai amounts of water, coinciding with organogel formation. further addition of
water leads to a sharp decrease in viscosity, owing to the separation of a homogenous
gel from the remaining low-viscosity fluid. Finaliy, the solidification ofthe separated gel
into a non-transparent solid precipitate occctrs at even higher concentrations of polar
soivent. More extensive physicochemical characterization can be found in the review by
Shchipunov [42].
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3.1.2.2. fatty acid derived organogels
Other biocompatible organogels extensively investigated in drug delivery are SMS
(Span 60) and sorbitan monopalmitate (Span 40) organogels (Table I). Murdan et al.
[43-461 were the flrst to report organic solvent gelation by these two compounds, both in
the presence and absence of an aqueous phase. Anhydrous gels were obtained by
dissolving low concentrations (i-10%) of the organogelator in aikanes (C>5), isopropyl
myristate, and various vegetable oils at 60°C. Subsequent cooling of the system yielded
white thermoreversible gels at room temperature. Alternatively, the drop-wise addition
of an aqueous phase, in the form of either water or a suspension of niosomes (surfactant
bilayer vesicles) to the hot organic surfactant solution yielded upon cooling a water-in
ou (w/o) or a vesicle-in-water-in-oil (v/w/o) organogel system, respectively.
As with alt gelling mechanisms, the gelation point corresponds to decreased solvent
gelator affinities resulting in a structural transition, in this case from the isotropic phase
composed of reverse micelles to a system of entangled rod-shaped tubules that
immobilizes the solvent [46,47]. Further organization of the amphiphiles inside the
tubules was suggested to consist of concentric inverted bilayers, which as in the case of
LO were found to be stabilized by hydrogen bonds between water and the amphiphiles’
polar heads [44,46,48].
The classification of these non-ionic surfactant organogels as either solid- or fluid
matrix systems is less clear-cut than in the preceding cases. Although the bilayer
arrangement within tubules intuitively suggests a certain fluidity and possible exchange
of surfactant molecules with the surrounding bulk liquid, certain studies tend to point
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away from the fluidity hypothesis. Indeed, when viewed under polarized light, the
tubular aggregates exhibited crystallinity [48]. Nevertheless, X-ray diffraction
measurements have shown the inverted bilayers to increase in width upon the addition of
water, suggesting the accommodation of the aqueous phase between opposing polar
groups of the amphiphilic bilayer [44] pointing towards the plasticity of the systems. A
saturation point was reached, afier which excess water accumulated in separate droplets
bound by surfactant film at the interface, followed by the eventual breakdown of the gel
as aggregate integrity is substantially lost. The continuous modulation of the system to
accommodate the polar solvent suggests a dominating fluid character for the constituting
matrix.
3.2. Polymeric gelators
Polymeric gelators behave similarly to their LMW counterparts, solidifying organic
solvents based on physical intermolecular interactions. Polymeric gels can vary from
linear to star-shaped polymers. Three such polymeric systems with common or potential
uses in drug delivery will be presented in this section.
Poly(ethylene) organogels (P0) are commonly used as ointrnent bases and are composed
of 5% low molecular weight poly(ethylene) in mineral oil (Plastibase®) (Table I) [49-
51]. The polymer is dissolved in the oil at about 130°C and ‘shock-cooled”. This leads
to the partial precipitation of the polyrner chains and the formation of a colorless
organogel [49-5 1]. Also of common application in pharmaceutics are copolymers of
methacrylic acid (MAA) and methyl methacrylate (MMA) in 1:1 (Eudragit L®) and 1:2
(Eudragit S®) molar ratios (Table I). These can be used in the preparation of organogels
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that have been evaluated as rectal sustained release preparations [52,53]. In the available
studies, such gels typically consisted of a mode! drug dissolved in propylene glycol
containing high concentrations of the gelling polymer (30 and 40 % for 1:1 and 1:2
P(MAA-co-MMA), respective!y). Basic drugs were found to weaken the gel structure
more than acidic drugs, a phenomenon attributed to an increased disturbance of the
hydrogen-bond interactions between polymer and propy!ene glycol molecules by the
former.
Recent!y, Jones et al. [54] presented the preparation of star-shaped a!kylated
poly(glycero! methacrylate) amphiphiles, capable of forming polymeric micelles in
pharmaceutica!!y-acceptab!e apolar solvents such as ethyl oleate. It was found that
organoge! formation occurred at high polymer concentrations (> 10 %) when the latter
were derivatized with medium-length C12 and Ci4 alky! chains. On the other hand,
gelation occurred at much lower concentrations ( 1 %) in the case of C18-derivatized
polymers, showing the importance of intermolecular van der Waa!s interactions in the
gelation mechanism. Hydrogcn bonding via the hydroxyl groups of the core polymers
was suggested to be a driving force for gelation. The systems were shown to increase the
so!ubility of hydrophilic compounds in oils, making them potentia!!y useful for the
preparation of anhydrous peptide formulations. Potential drug delivery from these
organogels remains an interesting option to be exp!ored.
j4. Organogels in drug delivery
Despite the large abundance and variety of organogel systems, relatively few have
current applications in drug delivery, owing mostly to the lack of information on the
biocompatibility and toxicity of organogelator molecules and their degradation products.
This section focuses on organogel systems that have been geared towards
pharmaceutical applications and are at various stages of devetopment, from pretiminary
in vitro experiments to clinical studies. Table I provides a summary of the key drug
delivery studies conducted using organogels.
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Table I: Organogel formulations used in drug delivery
.
RouteofOrganogelator used in formulation Study conducted Model drugs
a d min ist ratio n
Clinical trials Diclofenac [55-571
O R1
r N In vivo skin
II Piroxicam [5$]
N
\\_0 permeation and Tetrabenzamidine [59]
—
efficacy
0-’R2 Scopolamine andLecithin Transdermal In vitro skin Boxaterol [39]
permeation Propranolol [60]
R1 ami R2 = various fatt acids of N icardipine [61]
hich Iinoldc (55%) and palmitic
(13%) acids Aceclofenac [62]
In vitro release Indomethacin and
Diclofenac [63]
Mixture of mono-, di-,Glyceryl fatty Levonorgestrel and
. and tri-glycerides Transdennal In vivo efficacy
acid esters Ethmyl estradiol [64]ofC16 and C fatty acids
o
H II
CH3(CH2)10N,-1Ç__(CH2)3CH3
N-lauroyl-L- H
glutamic acid di- Transdermal In vitro release Haloperidol [65,66]
n-butylamide
HN
CH2)3CH3
Poly(ethylene)
—f-CH2_-_CH2I—— Transdermal In vitro release Spectrocin [49]
HO OH Nasal hi vitro release Propranolol [67]
Sorbitan II
monostearate OR Oral hi vitro release Cyclosporin A [68](SMS) or
H Subcutaneous 2
molaureate O BSA and HAand In vivo efficacy F4 44 69R = (Ci-I2)1,CHor (CH2)1CH intrarnuscular
O In vitro/in vivoH Rivastigmine [1$]
N-stearoyl c- CH3(CH2)NN 0R release
alanine methyl Subcutaneous In vitro/in vivo
or ethyl ester release and Leuprolide [70]
R CH orCH2CH efficacy
P(MAA-co
MMA)3 t H3 Rectal In vivo efficacy Salicylic acid
P(MAA-co- CH2C CH2—C
MMA) and COOH COOCH3 m Buccal hi vivo efticacv BSA’
cPAA1
BSA: bovine serum alburnin (antigen model)
2 HA: haernagglutin (antigen model)
P(MAA-co-MMA): poly(methacrylic acid-co-methylmethacrylate)
4CPAA: crosslinked poly(acrylic acid)
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4.1. Dermal and transdermal formulations
Drug delivery into the skin layers (cutaneous or dermal delivery) and beyond
(percutaneous or transdermal delivery) is advantageous because it provides a non
invasive, convenient mode of administration without the first pass degradation of the
active ingredient, an important aspect for highly Iiver-rnetabolized molecules [61].
Despite the great potential of dermal and transdermal drug delivery systems, relatively
few drugs are available as topical formulations. The difficulty in developing such
systems lies mostly in the circumvention of the barrier properties of the stratum corneum
(SC). Nevertheless, with absorption issues at least partially circumvented by the use of
permeation enhancers, a number of vehicles, of which organogels, have been developed
for transdermal delivery [31]. An important advantage of such systems is their general
case of preparation, the latter typically consisting in simple dissolution of drug and
gelator in the liquid medium.
An important class of permeation enhancers with wide use as organogel components are
saturated and unsaturated fatty acids [71]. Amongst these, oleic acid and isopropyl
palmitate are particularly interesting for their common use in organogels. It is thought
that the precise mechanism of action is the penetration of the fatty acid moieties into the
lipid bilayers of the SC and the consequent creation of separate domains which become
highly permeable pathways [721.
Surfactants [71,73] and phospholipids [74] constitute another class of molecules proven
to possess permeation enhancing properties. These compounds likely absorb into the SC
and increase tissue hydration, consequently increasing drug permeation in the case of
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hydrophilic active agents. Fluidisation of the lipid bilayer, with eventual extraction of
lipid components is also thought to occur for both surfactants [72,75] and phospholipids
[63,76,77].
Despite the presentation of these generalized trends, it should be said that perrneation
enhancing properties are highly dependent on the overal! formulation and more
specifically on the physicochemical properties of the permeating drug molecule [78].
Caution should therefore be employed in drawing conclusions about particular systems
soÏely based on the potential effects ofindividual components.
4.1.1. Lecithin
The most investigated organogels for topical delivery are LO (Table I) a recent review
published on the topic provided a relatively exhaustive list of active agents loaded in
such formulations [3!]. LO present several favourable characteristics for transdermal
delivery owing to their amphiphilic nature. Firstly, the lecithin and oil can efficiently
partition with the skin and provide an enhanced permeation as has been shown for
several mode! drugs [3 9,60-62]. The effect was attributed to both the solvents used
(isopropy! pa!mitate, ethyl oleate, etc.) [63] as well as to the !ecithin itself [58,60]. The
amphiphi!ic nature of LO also allows so!ubi!ization of guest mo!ecules in either the
organic or aqueous phase, thus permitting the incorporation of molecules with diverse
physicochemica! character, such as vitamins A and C [32], as well as peptides [39].
In the case where a therapeutic effect is needed in a localized region close to the skin
surface, transderma! delivery offers net advantages over oral administration, main!y in
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terms of lowered systemic side-effects. This potential advantage has been nicely
demonstrated for LO in several laboratories and clinical studies. Nastruzzi et al.
observed a levelling in subcutaneous tumour growth in mice treated transdermally with a
LO containing an anti-tumoral agent (tetra-benzamidine) [59]. When the LO was applied
away from the affected region, the tumour continued to grow, demonstrating lower
systemic versus local effects of the system. Similarly, the incorporation of non-steroidal
anti-inflammatory drugs (NSAIDs) into LO has been given particular attention because
of the potential to apply the analgesics close to the site of action, as could be useful in
the case of rheumatism. With these scopes in mmd, transderrnal delivery of NSAIDs
(aceclofenac [62] and piroxicam [58]) from LO was demonstrated in standard
permeation studies. Also, several double blind, randomized clinical trials on patients
suffering of various musculoskeletal ailments (orthoarthritis, lateral epicondylitis,
sprains, etc.) and treated transdermally with 1-2% diclofenac in LO, revealed significant
improvements in terms ofanalgesic efficacy cornpared to placebo [55-57].
Histological studies on excised human skin showed no toxic effects when LO were
applied to the skin for prolonged periods oftime [39]. In a study on over 150 volunteers,
acute irritation attributed to LO application was rare and discrete. Similarly, a low
cumulative irritancy potential was demonstrated (1150, irritation time of 50% of the test
population, equal to 13 days) [79]. Overall, LO are currently the most advanced of ah
LMW organogel systems; LO ointment bases are commercially available for magistral
preparations [55].
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4.1.2. Fatty acid-derived sorbitan organogels
Organogels consisting solely of non-ionic surfactants (prepared by dissolving 20% SMS
in liquid surfactants, e.g. polysorbate 20 or 80) were tested for their safety as topical
formuLations [73]. The surfactants being known permeation enhancers, adverse effects
resulting from modifications in skin structure were investigated on shaved mouse as well
as on human skin. In both cases, no significant increases in blood flow and in epidermal
irritation was observed. Some epidermal thickening was however noticed, suggesting a
marked interaction between the surfactants and SC components. Overail, the gels were
regarded as safe and well-tolerated by volunteers when applied daily for 5 consecutive
days. However, to the best of our knowledge. no skin permeation or effïcacy studies
using these organogels have been published to date.
4.1.3. Organogels based on other low molecular weight gelators
Pénzes et aï. investigated the transdermal delivery of piroxicam from organogels
composed ofglyceryt fatty acid ester gelators in pharmaceutical oils [80,81]. The in vivo
skin penetration of the drug, evaluated by measuring the anti-infiammatory inhibition of
oedema afier treatment, was found to be superior for glyceryl fatty acid ester organogels
as compared to traditional topical formulations such as liquid paraffin [81]. Chan e! aï.
[65,66] reported the use of a long acyl-chain glutamate-based gelator (N-lauroyl-L
glutarnic acid di-n-butylamide) at concentrations of 2-10% to gel isostearyl alcohol and
propylene glycol, yielding translucent and opaque gels, respectively. In vitro permeation
studies on human skin using haloperidol, an anti-psychotic drug, showed facilitated
permeation upon incorporation of 5% limonene, a known permeation enhancer.
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4.1.4. Poly(ethylene) organogels
Contrary to hydrogels [$2-$5], very few polymeric organogels have been geared to
pharmaceutical applications. The only two such systems having been widely tested for
drug delivery applications are poly(ethylene) and P(MAA-co-MMA) organogels.
In a study dating back to the 1950s and involving 300 patients, P0 patches were shown
to be non-irritating and to have low sensitizing properties [491. In a related investigation,
326 patients were treated with spectrocin-containing P0 and compared with patients
treated with spectrocin in petrolatum base alone. Both antibiotic ointments cleared
pyoderma and secondarily infected eruptions in 3-5 days, but it was found that the P0
provided a faster, more efficient release. Poly(ethylene) xvas also used in the formulation
of5-iodo-2’-deoxyuridine for the treatment of oral herpes simplex lesions. A 10% drug
loaded formulation showed a resolution of herpetic lesions in 3-days afier treatment
initiation, compared to 1-2 weeks in untreated control patients [50]. Similarly, P0 were
employed as a base for a patch testing metal allergens [51]. The bioavailability of nickel
antigens from the P0 patch applied to the back of patients was found to be as good as
for the control methylcellulose patch.
4.2. Parenteral depot formulations
Anhydrous and water-containing organogels were formulated for depot formulations
using SMS and different gelation modifiers (polysorbates 20 and 80) in various organic
solvents and oils. These gels were shown to be suitable for the controlled release of
drugs and antigens.
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SMS organogels containing either w/o or a v/w/o emulsions were investigated in vivo as
delivery vehicles for vaccines using bovine serum albumin (BSA) and haemagglutin
(HA) as mode! antigens [43,44,69]. Intramuscular administration of the v/w/o gel
yielded the longest-lasting depot effect (42 h). This could be readily explained by the
combined barriers to diffusion present in this formulation (niosomes and gel matrix)
[69]. Nevertheless, the release was relatively short-lived, likely due to the percolation of
interstitial fluid into the gel, causing it to fragment and emulsify [45]. Based on the
observed phenomena, the release mechanism for hydrophilic antigens vas assumed to be
driven by gel disintegration. The studies also showed that both the w/o and v/w/o gels
possessed immunoadjuvant properties and enhanced the total primary and secondary
antibody titres to the HA antigen in mice.
Controlled release of the contraceptive steroids levonorgestrel and ethinyl estradiol was
achieved by Gao et aï. from subcutaneously-injected biodegradable organogel
formulations prepared from glyceryl ester fatty acids in derivatized vegetable oil [64].
Despite an inflammatory reaction in injected rats lasting up to 7 days, the gel
formulations proved their efficacy by completely blocking the estrous cycle of female
rats up to 40 days. The duration of the biological effect was of the same order of
magnitude as the tirne needed for geL degradation, suggesting the latter phenomenon to
control drug release from the implant.
Subcutaneously-inj ected in situ-forming organogels prepared from L-alanine derivatives
in safflower ou were used in the long-term delivery of teuprolide, a luteinizing hormone
releasing hormone agonist used in prostate cancer [701. The gels were shown to sÏowly
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degrade and release the therapeutic peptide for a period of 14 to 25 days. The efficacy of
the system was demonstrated by the induced chemical castration (inhibition of
testosterone secretion), lasting up to 50 days (figure 9). More recently, the same
systems, using the N-stearoyl L-alanine methyl ester organogelator in safflower ou, were
used in the sustained delivery of rivastigmine, a cholinesterase inhibitor used in the
treatment of AÏzheimer’s disease [1$]. Following subcutaneous injection, the oleogels
provided a 5-fold lower burst effect than control ou formulations, followed by sustained
release ofthe drug for up to 11 days. Histology studies showed these organogels to have
a good biocompatibility profile over an $-week evaluation period [161. Overali they
represent a promising platform for long-term sustained drug delivery.
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Figure 9: A) Plasma concentrations of leuprolide afier the subcutaneous administration
of a control w/o emulsion (squares) and various organogel formulations (circles and
triangles; SAM and SAE: N-stearoyl methyl or ethyl ester, respectively). B) Plasma
concentrations of testosterone after the administration of the formulations in a). The
dotted une represents the chemical castration threshold (mean + SEM, n=5-6).
Reproduced with permission from reference [70].
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4.3. Oral and trans-mucosal formulations
The only example found in the literature of oral organogel formulations was that of
SM$ systems recently investigated by Murdan et aï. [6$]. Cyclosporin A, a powerful
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immunosuppressant used afier organ transplantation, was incorporated in organogels
varying in nature from highly hydrophobic (SMS in sorbitan monoleate) to more
hydrophilic systems (SMS in polysorbate $0). Upon administration to beagle dogs, the
hydrophilic organogels allowed less drug absorption than the hydrophobie formulations,
likely due to the absence of lipophilic domains in which the drug could remain soluble
once in contact with the aqueous gastric medium. The hydrophobie organogels showed
absorption profiles similar to those of the commercially available Neoral®
microemulsion formulation.
Organogels composed of P(MAA-co-MMA) have been tested as suppository
formulations. In vitro dissolution pattems ofsalicylic acid from organogels composed of
1:1 and 1:2 P(MAA-co-MMA) (Eudragit L® and Eudragit S®, respectively) [53] showed
an initial burst of drug release in both cases, followed by a slow release phase. Salicylic
acid followed a zero-order release from 1:1 P(MAA-co-MMA) organogels, providing
strong evidence for a surface erosion release mechanism with negligible diffusion. On
the contrary, the same drug was released from 1:2 P(MAA-co-MMA) organogels in a
linear function vers us the square root of time, suggesting a diffusion-controlled release
mechanism. Although an explanation was flot provided by the authors, it can be
hypothesized that this difference in release profiles is due to the relative hydrophilicity
of the two copolymers. The more hydrophilic 1:1 copolymer allows more water
penetration into the gel matrix, giving rise to erosion-controlled release; rneanwhile
water penetration into the matrix of the more hydrophobie 1:2 copolymer is more
limited, yielding a diffusion-controlled release. In vivo evaluation in rabbits of 1:1
P(MAA-co-MMA) gels, containing salicylic acid or ketoprofen, demonstrated a
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sustained release with area-under-the-curve values comparable to conventional
suppositories (WitepsolR H-15) [52]. Drug absorption from the organogels was increased
by a factor of 1.5 to 1.8 afler incorporation oC 10% linoleic or oleic acid, which are
known permeation enhancers.
Ethanol-based organogels composed of 1:2 P(MAA-co-MMA) and a crosslinked
poly(acrylic acid) polymer (Noveon AA1®) were tested in rabbits as mucoadhesive
films for immunization via the buccal route [86]. The antigen specffic IgG titer in serum
was found to be similar between rabbits having undergone buccal versus conventional
subcutaneous immunization. Although the authors reported higher titer levels afier 28
days for the buccally-immunized rabbits, the comparison seems biased given that
immunization for the buccal and subcutaneous routes was achieved by different means.
using plasmid-DNA encoding for the antigen versus the antigen itself, respectively.
Nevertheless, the feasibility of buccal immunization using the novel bilayer films was
successfully demonstrated.
Transnasal sustained release of propranolol hydrochioride, a -receptor blocking agent,
was obtained from biocompatible organogels consisting of SMS in isopropyl myristate,
and containing small amounts ofwater [67]. A potential advantage of this delivery route
is the circumvention of the first pass metabolism. which in the case of propranolol can
reach 50-70% afier oral administration. Due to water percolation and emulsification of
the gel, the diffusional drug release, vas found to change with time. Sirnilarly. the SMS
concentration was shown to have an optimum for achieving maximum release-
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retardation. Unfortunately. even for the optimized gel formulation, the tubular network
was shown to be completely disassembled within 6 h of in vitro exposure to water.
Considerable improvements to the in vivo stability’ of these systems are needed to allow
for convenient use as drug delivery systems.
5. Summary and conclusions
Given the strict requirements needed for gelation, as well as the relatively recent interest
granted to organogels, many important questions stili remain unanswered. for one, the
precise thermodynamic and kinetic factors goveming the stability of gelator fibers in the
organic sotvent need to be explored. Such knowledge could be applied to the systematic
design of gelators yielding stable organogel systems. furthermore, gel components
could be chosen according to their compatibility with intended applications, such as non
toxic solvents for pharmaceutical formulations.
Organogels present very interesting advantages as drug delivery formulations, amongst
which their case of preparation and administration. Some organogels are currently
limited by the fast diffusion of LMW drug molecules out of the matrix and/or by water
infiltration into the latter. Nevertheless, optimization of sustained drug release duration
is generally thought possible by fine-tuning the organogelator structure [171 and possibly
the nature ofthe organic phase.
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CHAPTER 4
Article: In situ-forming oleogel implant for stistained
release of rivastigmine
5$
1. Abstract
Purpose: To provide a simplified dosing schedule and potentially reduce side effects
associated to plasma peak concentrations, an in situ-fomiing oleogel implant was studied
for the sustained release of rivastigmine.
Methods: The gel was prepared by dissolving 5 - 10% (w/w) N-stearoyt L-alanine
methyl ester (SAM) organogelator in safflower ou containing either dissolved
rivastigmine or its dispersed hydrogen tartrate salt. Rheological analysis, differential
scanning calorimetry, infrared spectroscopy, and electron scanning microscopy were
calTied out in order to assess the impact of drug incorporation on the oleogel; this was
followed by in vitro and in vivo release studies.
Resuits: A weakening of intermolecular interactions was suggested by gel-sot transition
temperature drops of 10-15°C upon incorporation of dissolved drug. Meanwhile, the
dispersed drug sait induced minimal or no changes in the transition temperature. Gels
containing dispersed rivastigmine had the lowest burst in vitrO (<15% in 24 h). In vivo
the 10% SAM formulation containing dispersed rivastigmine provided prolonged
rivastigmine release within the therapeutic range for up to 11 days, with peak plasma
leveis well below the toxic threshold and up to five times lower than for the control
formulation.
Conclusions: Ihis study establishes SAM gels to be a promising option for a sustained
release formulation in the treatment of Alzheimer’s disease.
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2. Introduction
Alzheimer’s disease (AD) is the most common form ofdementia amongst elderly and is
estimated to afflict 1$ million people worldwide [1]. findings of the significant
cholinergic deficit in AD patients [2,3] led to the common treatrnent involving
cholinesterase inhibitors (ChEIs) that facilitate neurotransmission in remaining
cholinergic neurons [4] and delay the decline of functional and cognitive ability [5].
ChEIs are presently administered orally, once to twice daily [6]. In unsupervised older
adults suffering of AD, treatment compliance [7] and adherence [8,9] might be
problematic, which could potentially compromise the already modest efflcacy of ChEIs
[10]. Adverse effects are reported to be the main reason for treatment cessation [8], and
there is evidence that these can be reduced with more frequent, smaller doses [11].
These observations lcd to the hypothesis that a ChEI sustained release formulation
would entail a possible improvement in treatment adherence and compliance, as a result
of decreased side effects and simplifled dosing regimens, respectively, while alleviating
responsibility and workload for caregivers.
Despite the potential benefits of a sustained release of ChEIs, there have only bcen few
and preliminary investigations to this respect. A number of studies have investigated the
encapsulation of huperzine A into biodegradable microspheres of poly(d, Ï-lactic acid),
PLA, and poly(d,Ï-lactide-co-glycolide), PLGA [12-14]. Huperzine A is a plant-derived
ChEI that is currently approved for the treatment of AD in China. To date, sustained
release formulations have been investigated for only two FDA-approved ChEIs. Release
studies oftacrine from PLGA microparticles [15] showed the potential ofdrug delivery
over prolonged periods. The major problem with tacrine is its marked hepatic toxicity,
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which bas limited its use in favour of the better-tolerated second-generation ChEIs
(rivastigmine, donepezil, and galantamine). Out of these, rivastigmine alone has been
investigated for sustained release (transdermal patch) [16].
There has been increasing interest in developing parenteral sustained-release systems for
long-term drug delivery, microparticles being the most studied of such systems [17]. In
situ forming implants, such as those cornposed of organogels, are also gaining in
popularity due to the inherent advantages of their ease of preparation and administration
[18]. Inspired by the work of Bhattacharya et aï. who demonstrated gelation of a wide
variety of organic solvents by alanine-based gelators [19], our group further investigated
the thermoreversible gelation of various pharmaceutical oils by alkyl-chain derivatized
L-alanine at concentrations of 10% (w/ii’) or less [20,21]. Gelling is induced by the self
assembly of gelator molecules through van der Waals interactions and hydrogen
bonding between alkyl chains and polar head-groups, respectively. The network of
gelator aggregates formed immobilizes the ou and yields a semi-solid system. When
injected subcutaneously to rats, the oleogel degraded over several weeks and histological
analysis revealed the implants to be biocompatible [21]. A subsequent study showed the
first use of these gels for the sustained release of leuprolide for 14-25 days [22]. In the
present work, N-stearoyl L-alanine methyl ester (SAM) oleogels containing rivastigmine
(figure 1) were investigated as in situ forming implants for long-term drug-delivery,
with potential use in AD treatrnent. The physicochernical effects of drug incorporation
into the gel were studied and formulations were optimized for minimal in vitro burst
effect. Sustained release of rivastigmine from the injectable implants was demonstrated
in a pharmacokinetic study on rats.
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a) b)
H3CNHOCH3
figure 1: Molecular structures of a) rivastigmine base and b) N-stearoyl L-alanine
methyl ester (SAM).
3. Materials and methods
3.1. Materials
N-methyl-2-pyrrolidone ÇNMP), amylamine, isopropyl alcohol, hydrogcn peroxide,
magnesium suiphate, sodium phosphate dibasic, trifluoroacetic acid (TFA), and sodium
chloride were purchased from Sigma-Aidricli Canada Ltd. (Oakville, ON, Canada).
Dichioromethane and HPLC-grade acetonitrile (ACN) were obtained from ACP (St
Leonard, QC, Canada). Sodium azide was purchased from American Chemicals Ltd.
(Montreal, QC, Canada). Super Refined safflower ou and rivastigmine hydrogen tartrate
(RHI) were kindly provided by Croda Inc. (Toronto, ON, Canada) and Zentiva (Prague,
Czech Republic), respectively. Rivastigmine base (RB) was extracted from RHT as
described below. Deionised water was generated using a Millipore Milli-Q system
(Bedford, MA). SAM was synthesized as previously described [21]. RHI was tritium
labelled to a specific activity of 10 Ci/mmol by Arnerican Radiolabeled Chemicals Inc.
(Saint-Louis, MO).
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3.2. Preparation of Implants
Iwo types of gel formulations using different drug incorporation rnethods were
investigated.
3.2.1. Dispersed-RHT Gels
For this type of formulations, the RHT powder (mean diameter (d11) = 25 + 14 tm,
measured by light scattering in suspension on a Beckrnan Coulter LS230, Mississauga,
Ontario, Canada) was dispersed in safflower oil at concentrations up to 5% (w/w,). SAM
organogelator was added to the ou phase in concentrations up to 10% (w/w). The
mixture was vortexed and heated until dissolution of the organogelator. Upon cooling,
the solution set to a gel containing dispersed drug particles. Unless otherwise specified,
10% (w/w) NMP was subsequently added to formulations, in order to decrease the gel
viscosity and facilitate injection through conventional needles. Afler NMP addition, the
gel was heated and vortexed again in order to reform a homogenous dispersion.
3.2.2. Dissolved-RB Gels
For this type of formulations, an extraction was first performed on RHT in order to
isolate the RB moiety. This was doue by dissolving the drug sait in deionised water and
reacting it with 5 mol eq. of amylarnine, thus neutralizing the base rnoiety and allowing
the formation of an amylamine-tartrate ion pair. RB was extracted from the reaction
mixture in dichloromethane, which was subsequently washed with three portions of
water and dried over magnesium sulphate. The solution was filtered and the solvent
evaporated to yield the RB (oily appearance). Product identity was confirmed by
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‘H-NMR. The RB was directly dissolved in the safflower ou and the rest of the gel
preparation was carried out as outlined above.
3.3. Characterization
3.3.1. Rheology
The rheological properties of the organogels were measured by an AR2000 (Advanced
Rheorneter 2000, TA Instruments, New Castie, DE). with parallel plate geometry
(diameter of 40 mm). 10 ¾ (w/w) SAM organogels in safflower oil, with 4 ¾ (w/w)
dispersed RHT or dissolved RB was heated to 80°C and the formulations were placed
between the parallel plates. The final thickness of the material coat between the plates
was 650 to 750 jim. The film was cooled at 4°C to form the gel. To determine the linear
regime ofthe gel, the oscillatory strain sweeps were performed in the y strain range from
0.003 to 50 % at 1 Hz. The linear regime is characterized by constant dynamic moduli
(storage modulus, G’, and loss modulus, G”) that are independent of strain amplitude. In
this regime, G’ and G” have been measured as a function of the angular frequency (0.1
to 10 Hz) at 25 ± 0.1°C. The gel—sol (TGS) transition temperature was determined by
measuring G’ and G” variations at constant strain and angular frequency of 0.05 % and
1 Hz, respectively, with temperatures scanned between 25 and 80°C at I °C/min.
3.3.2. Differential Scanning Calorirnetry (DSC)
Thermograms of dissolved-RB and dispersed-RHT gels varying in drug concentration
were recorded on a 2910 TA Instruments DSC system (New Castle, DE). The
calorimeter was controlled with a Thermal Solutions (Version 1.4E) interface and peak
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integration was carried out using the Universal Analysis software (Version 2.5H), both
from TA Instruments Inc. The instrument was calibrated with indium. Formulations
were weighed into aluminum pans that were subsequently sealed. Temperature was
scanned between 5 and 90°C at 10°C/min. The reported gel-sol transition temperatures
(TGS) corresponded to the maximum of the endothermic peaks. Six replicate analyses
were conducted per formulation with one scan per sample.
3.3.3. Thermal Fourier-transform infrared (FTIR) spectroscopy
Infrared spectra of gels varying in RB concentration were recorded as a function of
temperature on a Bio Rad FTS-25 spectrometer (Bio-Rad Laboratories, Randolph, MA)
equipped with a water-cooled globular source, a KBr beam splitter, and a deuterated
triglycine suiphate detector. The concentration of the organogelator was fixed at
10% (w/w) SAM and the concentration of RB dissolved in the formulation was taken to
be 0, 4, and 40% (w/w). Once prepared, the gel was liquefied by heating and deposited
between two Caf2 windows separated by a 5-jim Teflon spacer. This assembly was
placed in a brass sample holder whose temperature was controlled by Peltier
thermopumps. Starting at room temperature, the sample was heated up to 75°C in 5°-
increments. At each temperature. the sample was equilibrated for 5 min before data
acquisition. Each spectrum was the average of 80 scans with a nominal resolution of 2
cm’. Triplicates of each formulation were tested. Spectra were analyzed using the
GRAMS software (Galactic Industry, Salem, NH).
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3.3.4. Microscopy
Environmental scanning electron microscopy (ESEM) images were obtained on a
Hitachi S-3000 variable pressure scanning electron microscope equipped with an
environmental scanning electron detector (Hitachi, Tokyo, Japan). Accelerating voltage,
operating pressure, and working distance were set to 20 kV, 120 Pa, and 9 mm,
respectively. Samples studied were oleogels containing either RB, RHT, or no drug,
prepared as previously described, as well as “dried gels” prepared by forming 10% SAM
gels in toluene and evaporating the solvent overnight, directly on the analysis surface.
Optical microscopy images of drug-free oleogels were obtained on an Axiovert S100
microscope (Carl Zeiss, Welwyn Garden City, UK) equipped with an integrated digital
camera.
3.4. In vitro release of rivastigmine
3.4.1. Release study
Dissolved-RB and dispersed-RHT gels were prepared as described above. The
organogelator concentration was varied for both types of gel up to 10% (u’/w). NMP was
added to some gels to test its effect on the release rate. The concentrations of ail
components in the formulation were calculated disregarding the amount of added NMP,
since the solvent is expected to quickly diffuse out of the formulation upon contact with
the release medium. The gels were loaded into cylindrical dialysis bags (MW cut-off
100 000 g/mol, 500 tL) (DispoDialyzer. Fisher Scientific, Montreal, QC, Canada) using
a syringe fitted with a 20-G, 1 ‘/2 needle. The dialysis bag was placed in 100 mL of
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phosphate-buffered saline (PBS) (104 mM NaH2PO4, 36 mM NaC1, 0.1% w/v NaN3, pH
7.4) at 37°C and agitated at 135 rpm. Tripiicate 1-mL samples were collected from the
release medium at 15, 30 mm, 1, 1.5, 2.5, 4, 6, 9, 12, 24, 48, 72 h, 7, and 14 days, with
replacement of sampled volumes by fresh PBS buffer. Release kinetics were performed
under sink conditions (knowing that the solubility of rivastigmine in PBS exceeds
1 mg/mL and the drug concentration in the release medium was at ail times below
0.2 mg/mL). Collected samples were immediately analysed by high performance iiquid
chromatography (HPLC) using the method described below. Concentration values at
each data point were corrected for sampling and dilution as previously described [23].
Each formulation was tested in triplicate.
3.4.2. HPLC method
In vitro release samples were anaiyzed using a modified iiquid chrornatography rnethod
previously published [24]. A Gilson Model 302 HPLC system (Gilson, Middletown, W1)
equipped with a Gilson 234 autoinjector, a Gilson 106 pump, and a Gilson 151 dual
wavelength UV-detector was used. An Altirna guard column (C 1$, 4.6 x 7.5 mm, 5 jim)
(Mandel, Guelph, ON, Canada) was placed upstream of the analytical column, an
XTerra (RP-18, 4.6 mm x 250 mm, 5 tm) purchased from Waters (Mississauga, ON,
Canada). A mobile phase of water/ACN (78/22 v/v), containing 0.1% (v/v) TFA, was
used at a flow rate of 1 mL/min. The injection volume and detection wavelength were 20
jiL and 210 nm, respectively.
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3.5. Pharmacokinetic study
Ail experimental procedures involving animais were conducted foilowing a protocoi
approved by the Animai Care Committee of the University of Montreal and compiied
with The Guide for the Care and Use of Laboratory Animais (NIH Publication no. $5-
23, revised 1996). Maie Long Evans rats (200 - 225 g) (Charles River Inc. St-Constant,
QC, Canada) were housed for 1 week under controiied conditions (12-h iight/dark
schedule, 24°C) prior to the start of experiments. Rat chow and tap water were provided
ad libidtirn. Ail formulation components were sterilized separateiy. SAM was steriiized
on dry ice by y-radiation at 25 kGy using a 60Co source (Nordion Inc., Lavai, QC,
Canada). Stabiiity of the organogelator afier sterilization was confirmed by mass
spectrometry and ‘H-NMR. The ou and NMP were filtered on 0.2-im
polytetrafluoroethylene fiiters. RHT was dissoived in water; the solution was spiked
with the appropriate amount of 3H-iabeiied drug (25 iCi/formulation) and steriiized
through a 0.2-tm nylon filter. Sampies were iyophiiized under sterile conditions to yield
a homogeneously-radiolabeiled drug powder. Using the steriiized ou, SAM, NMP, and
RHT, the final ou and gel formulations were prepared under aseptic conditions. A
controi RHT-saline solution was prepared by dissolving RHT in 0.9% NaC1 solution,
spiking the solution with radiolabelled drug (25 iiCi/formulation) and steriiizing the
final solution by filtration. The rats were divided into four groups (n = 6) and given a
single s.c. injection ofapproximateiy 400 IIL ofthe appropriate formulation in the lower
dorsal area using a 20-G syringe. Rats were injected with the foliowing approximate
rivastigmine doses: 10 mg/kg for saline formulations and 1$ mg/kg for oil and gel
formulations. The exact amount of injected formulation was obtained by weight
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difference of syringes before and afier injection. The tested formulations were a RHT
saline solution, as well as RHT dispersed in ou, in 5%, and in 10% SAM oleogels.
Blood samples (200 tL) were periodically collected from the subclavian vein of the rats
under isoflurane anaesthesia, and were subsequently weighed, digested using up to 1.5
mL So1vable (PerkinElmer, Groningen, The Netherlands) and 500 IIL isopropyl alcohol
to ensure solubility. The samples were incubated at 60°C for l-2 h to complete
digestion, afier which they were bleached using 1-1.5 mL hydrogen peroxide. Finally,
10-mL portions of Hionicfluor scintillation cocktail (PerkinElrner) were added to each
sample, which was vortexed, stored in the dark at 4°C for 24 h, and subsequently
counted on a liquid scintillation analyzer (Tricarb 2100TR, Packard, Meridan, CT).
Values of drug concentration in the blood (tg drug/g blood) were obtained from the
radioactivity count (dpm) of each sample by reporting the latter to the total radioactivity
to-drug ratio (dpm/ig drug) injected.
3.6. Statistical Analysis
Tests for significant differences between means of TGS, transition enthalpy (AHGS)
values, and pharmacokinetic parameters were carried out by one-way analysis of
variance (ANOVA), followed where necessary by the Tukey post-hoc test. Differences
were considered statistically significant for p<O.O5.
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4. Results and Discussion
4.1. Physïcochemical Characterization of Oleogel
4.1.1. Rheological analysis
The rheological analysis was initially perforrned as a function of applied strain (y) for
drug-free as well as 4 and 5% RB- or RHT-loaded oleogels, respectively, at a constant
oscillation frequency of 1 Hz (Figure 2a).
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A linear regime, corresponding to strain-independent storage and loss moduli (G’ and
G”) was measured up to a critical strain (y) value of 0.05%, beyond which a decrease in
G’ and G” was observed. Using a strain value within the linear regime (0.01%), G’ and
G” were measured at 25°C as a function of oscillation frequency (Table 1) and were
found to be relatively constant between 0.1 and 10 Hz (Figure 25). The G” value ofthe
drug free oleogel was found to be larger than 1/10 of the G’ value, this being
characteristic of a poorly elastic gel. Indeed, the oleogel exhibited a soft and waxy
aspect. When RB was dissolved at 4% in the formulation, G’ and G” values slightly
increased but remained within the sarne range as for the unloaded system. However, the
incorporation of dispersed RHT produced a Ï5-fold increase of G’ and G’. These
findings show that the dispersed drug irnproved the forrnulation’s mechanical strength as
previously observed for other gels containing physically dispersed particles [25].
Finally, the TGS was determined at a strain of 0.005% and a frequency of 1 Hz (Figure
2c). At room temperature, G’ was found to be higher than G”, a property characteristic
of a gel systems. As the temperature rose, G’ and G” decreased at different rates and
eventually crossed, marking the system’s transition to the sol-state. As shown in Table 1,
RB significantly decreased the TGS with respect to drug-free gels, while only a slight
difference was observed for RHT-loaded formulations.
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4.1.2. DSC
The effect of drug-loading on gel intermolecular interactions was evaluated based on
gel-sol transitions obtained by DSC. For sirnplicity, only the behaviour of gels during
heating cycles was investigated, however it lias been previously shown that SAM
oleogels undergo fully reversible transitions [21]. Analysis of oleogels containing
dissolved RB (Figure 3) revealed that TGS and enthalpies decreased as drug content was
progressively increased from 0% (drug-free gels) to 4, 20, and 40% (w/w,).
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Figure 3: DSC analyses showing gel-sol transitions for drug-free gels (o), for gels
containing 5% (w/w) dispersed RHT (.), and for gels containing RB dissolved at 4 (A),
20 (o), and 40% (w/w) (K). Curves are offset on the y-axis for improved clarity. AH and
TGS values were calculated from the area under the curve and the temperature
conesponding to the peak transition, respectively.
The drop in TGS, varying between 4 and 13°C, was found to be statistically significant
between any of the gels containing dissolved RB and the drug-ftee gel (Table 1). The
DSC data corroborated well with observations from rheology measurements, both
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methods indicating a decrease in TGS with increasing RB-loadings. Nevertheless, TGS
values determined by rheological analysis were found to be 10-15°C less than those
determined by DSC, an expected difference explained by the measurement of different
phenomena by the two techniques. DSC further showed that transition enthalpies
decreased more moderately and were found to be signiflcantly lower than for the drug
free gel only when extrernely high concentrations of RB (40% w/w) were added,
yieÏding a 39% decrease in this case. The observation of decreasing TGS and AHGS
suggests a weakening of organogelator interactions by the addition of rivastigmine. Gels
containing a dispersion of RHI salt (5% w/w) were also analyzed by DSC and were
found to have similar TGS and z\H6s values to the drug-free formulation. This indicates
that, contrary to dissolved RB, the dispersed RHT crystals do not influence the gel
structure at this concentration.
Table 1. Gel characterization: 10% (w/w) SAM oleogels containing various
concentrations of rivastigmine incorporated by dissolution or dispersion were
characterized by rheological analysis, DSC and IR (mean ± SD).
Rheology (n=3)
G’; G” (kPa) TGS (°C)
8.29 + 3.65:0 66.5+0.3
______________
1.35+0.91
22.52 ± 7.69;4 54.7 + 0.21.35 + 0.91
20 n.d. n.d.
40 n.d. n.d.
142.05 + 37.22Dispersion 5 64.0 ± 0.819.17± 11.72
vs. drug-ftee gel
b<005 vs. 4% (w/w) dissolved-RB gel
Cp<005
vs. 20% (w/w) dissolved-RB gel
vs. 40% (w/w) dissolved-RB gel
n.d.: not determined
Drug Rivastigmine
incorporation content
method 4Y0 (Ki/w)
Drug-ftee
Dissolution
DSC (n=6) IR (n=3)
AH (J/g SAM) TGS (°C) TGS (°C)
1.65 + 0.12 75.1 + 1.8 77.8+2.1
1.57+0.17 70.7+ t.a 75.8+4.1
1.31 + 0.27 65.6 + 1.6 a.b n.d.
1.05 ± 0.18 a 61.7 + 2.8 abc 56.4 + 0.6 ib
1.42 + 0.20 U 73.4 + o.s c.d n.d.
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4.1.3. FuR
To gain further insight into the effect of RB addition on the gelation process. hydrogen
bonding between SAM molecules in the absence and presence of dissolved drug was
studied by fTIR spectroscopy as a function of temperature (Figure 4). Two vibrational
components of the amide I group were studied, indicating the presence of species
identified as H-bonded (1649 cmj and free (1685 cmj amide carbonyl groups [21,26].
It is known that the gel-sol transition is associated with a hydrogen-bond disruption
between amide groups of organogelator molecules [21,26]. This gives rise to an abrupt
increase and a corresponding decrease in the peak intensities ofthe 1685 and 1649 cm
amide I components, respectively (figure 5).
H-bonded C=O
1648 cm1
oF)
ï
O CI-13
Amide I group
Figure 4: Thermal evolution, as probed by FTIR spectroscopy. The intensity ratio of
the amide I peak components (11685/11618) was monitored as an indication of H-bond
disruption between SAM molecules during gel heating from 20 to 75 °C. Arrows
indicate changes from the gel (low temperatures) to the Iiquid (high temperatures) state.
V
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By plotting the ratio of the peak intensity of these two bands (11685/11649) against
temperature, the TGS was determined from the inflection point of the corresponding
sigmoidal function (Table 1).
80
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Figure 5: FTIR analysis showing the proportion of free amide bonds in drug-loaded
gels, as determined from the hand intensity ratio of amide I peaks at 1685 and 1648 cm
(11685/11648), as a function of temperature for gels containing dissolved RB at different
concentrations: O (n), 4 (z) and 40% (w/w) (o) (Mean ± SD, n = 3).
The TGS values obtained from the IR experiment were very similar to those obtained by
DSC. The drug-free and 4% (w/w) RB gels showed a sharp increase in the 11685/11649 ratio
around 70°C, without the subsequent formation of a plateau, suggesting only partial
network disruption for these gels at 75°C (the maximum accessible temperature for our
experimental set-up). For gels with high RB concentrations (40% w/w), the FTIR study
showed the H-bond network to be disrupted at lower temperatures (—55°C). The
transition to the sol state appeared to be complete as the 11685/11649 ratio levelled off at
around 65°C. Contrary to DSC, the IR study was not sensitive enough to show an
interference of the dissolved drug with the oleogel structure at low drug-loading (4%
10 20 30 40 50 60 70 80 90
Temperature (°C)
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w/w). However, at very high drug-loading, the lowering of the transition temperature is
confirmed by both the DSC and IR studies. A hypothesis for the weakening effect ofthe
dissolved drug on the gel network is the reduction of hydrogen-bonding between
organogelator amide groups by competing interactions with the ester and amine
functionalities of rivastigmine. Despite this weakening effect, the formulations remain in
the gel state at physiological temperature, which permits their use as drug-loaded
implants.
4.1.4. Microscopy
An optical microscopy picture of drug-free, 10% SAM oleogel (Figure 6a) allowed
visualisation of the continuous network of fibrous SAM aggregates responsible for
gelation. furthermore, samples of drug-free as well as RHT- and RB-loaded oleogels
were analysed by ESEM (Figures 6b and e). The advantage of this technique over
conventional SEM is the possibility of imaging wet and/or non-solid samples in their
natural state, without sample preparation steps such as drying and metal coating.
Micrographs depicted only the gel surface topography and did flot allow the viewing of
the underlying gelator network. Only the crests of SAM aggregates were seen protruding
from the ou. The apparent aggregate size was found to be similar for drug-free gels
(Figure 6b) and those containing dispersed RHT (image not shown), while being
noticeably smaller in gels containing dissolved RB (Figure 6c). These observations seem
to corroborate with DSC and fTIR observations, suggesting that concurrent with the
hydrogen-bond disruption between SAM chains by RB, a corresponding reduction in
aggregate size is possible. In a further effort to visualise the gel network, the ou was
replaced with a volatile continuous phase.
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b)
_________
C) ‘r
_________
Figure 6: a) An inverted tube containing 10% (w/w) SAM gel is shown at room
temperature to demonstrate the cohesiveness of the system. Ihe inset shows an optical
microscopy image of the oleogel network. ESEM images of a I 0% (w/w) SAM b) drug
free oleogel and e) oleogel containing dissolved-RB (5% w/w). finally, an ESEM image
is shown of d) a dried formulation, obtained afier complete solvent evaporation from an
organogel of 10% SAM in toluene.
Although the gel structure may be different between the toluene- and oil-based
formulations, gelator network formation is common to both systems. Afier allowing
complete solvent evaporation from organogels of 10% SAM in toluene. ESEM was
carried out on the dried formulations (figure 6d). The micrograph clearly depicts the
three-dimensional gelator network housing interconnected channels (dark areas) lefi
100
empty b)’ the evaporated solvent.
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4.2. In vitro release
In vitro release kinetics were performed on ou and gel formulations (Figure 7)
containing either dissolved RB (solid symbols) or dispersed RHT (hollow symbols). No
truc correlation of the overali release profile with eventual in vivo behaviour is possible
given that enzymatic degradation plays a great role in the latter case. The main purpose
of this study was to optimize the formulation in terrns of minimal burst release, so as to
diminish the risk of adverse effects in vivo. It is known that side-effects of rivastigmine
are considerably reduced if titration of the drug is slowed down [27]. As shown in
f igure 7, drug diffusion from the dialysis bag was flot the rate-limiting factor, as
illustrated by the complete release of drug from the control RI-IT solution within 6-9 h.
NMP did not seem to play a significant role in the release mechanism, since
formulations prepared with and without the organic solvent showed comparable burst
releases (Figure 7). its incorporation in the formulation is however beneficial because it
facilitates injection at room temperature by partially disrupting the interactions between
organogelator molecules [21,22].
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Figure 7: In vitro release experirnents for formulations varying in SAM and NMP
content as well as in drug incorporation method (dissolution vs. dispersion). A control
RHI solution in PBS (X) was tested. Release experiments from formulations containing
dissolved RB are represented by solid symbols: ou formulation (.), 10% SAM gel with
t.) and without NMP (À); release experirnents from gels containing dispersed RHT are
represented by hollow symbols: ou formulation (o) and 10% SAM gel with (n) and
without NMP (z) (Mean ± SD, n = 3).
formulations containing dispersed RHT had a much lower burst than gels containing
dissolved R3, with about 10 vs. 70-90%. respectively, of total rivastigmine released in
12 h. This is due to the limited solubility of the drug satt in the oil medium and
consequently, the low amount of drug able to diffuse out of the implant. In fact. the
release from these gels nearly stopped afler the first day. with less than 15% ofthe total
drug released, confirming diffusion of the drug out of the formuLation to be minimaL.
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The in vitro release study showed very little, if any. differences between gels varying in
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organogelator concentration, especially in the case of gels containing dispersed drug.
Plourde et aÏ. [22] have demonstrated that the release of leuprolide from $AM oleogels
varied greatly with organogelator content. The drug used in this case was incorporated
into the gels via a water-in-oil ernulsion, which made the density of the gel fiber network
critical to the retention of ernulsified water droplets. However, in the case of a simple
dissolution or dispersion of the drug in the gel, the rate-limiting mechanisms of release,
namely drug dissolution and/or diffusion in the oily matrix, seem to be practically
unaffected by the density ofthe gel network, within the investigated range.
4.3. Pharmacokinetic Study
Owing to their considerably smaller burst effect, dispersed-RHT gels were chosen for
subcutaneous injection to rats. Gels varying in SAM concentration (5 and 10% w/w) as
well as oil and saline control formulations were studied. It is to be noted that the
rivastigmine dose injected in saline (10 mg/kg) was lower than for oil and gel implants
(1$ mg/kg) in order to avoid overdosing, since the former formulation allows rapid
systemic absorption of the entire dose. Blood concentrations of rivastigmine were
monitored over two weeks. In the days following implant injection, no dermal reaction
or apparent signs of toxic effects related to rivastigmine (e.g. dianhea, seizures) were
observed. The pharmacokinetic profiles and parameters of the injected rivastigmine
formulations are presented in Figure $ and Table 2, respectively.
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Figure 8: Blood concentration ofrivastigmine afier the s.c. administration ofa 10 mg/kg
dose of saline RHT solution (À), and 18 mg/kg doses of RHT dispersed in ou (.), in
5% (A), and in 10% (‘w/u,) SAM gel (o). (Mean ± SEM, n = 6) SEM rather than SD
values were used for the error bars in order to reduce clutter and improve the clarity.
Table 2. Pharmacokinetic parameters ofthe different formulations injected to rats (n=6).
0 2 4 6 8 10 12 14
.
. FormulationPharmacokinetic Parameter
Saline Ou 5% SAM gel 10% SAM gel
120+20 250+62 277+101 140+70
6.1+1.4 8.4+2.1 7.3+4.1 4.2±2.2
156+37 204+73 242± 102 48+17 bc
60 100+62 120±66 80+49
were not statistically different for the 4 formulations tested. This suggests a complete
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release of rivastigmine from ail formulations within the two weeks studied. However,
despite the lack of statisticai differences, a trend of decreasing AUC/DO can be observed
with increasing organogelator concentration (8.4 vs. 4.2 x 10 day(g blood’ for the ou
vs. 10% SAM formulations, respectively). This observation suggests the possibility of
slower, and potentialïy incomplete, release from the 10% SAM gels within the period
studied.
As expected based on the in vitro experiments, the saline formulation was rapidly (< 3 h)
absorbed into circulation, producing an important burst, afier which elimination drove
drug blood levels down to baseline values within 3 days. Contrary to the in vitro study,
there were marked differences among gels varying in SAM content. While both oil and
SAM formulations showed sustained blood levels within the therapeutic range (1 — 400
ng/mL) [28J for 11 days, the 10% SAM oleogels proved largely superior to the oil and
5% SAM formulations in terms of minimizing burst release (Cniax values up to 5 times
lower). The low peak plasma concentration (48 + 17 ng/g), being well below the toxic
threshold (400 ng/mL), would allow the administration of higher rivastigmine doses,
thus potentially increasing the delivery time. A hypothesis for the decrease in burst
release in the case of 10% SAM formulations is the higher density of their constituting
gelator network. The improved cohesiveness of these gels may reduce the subcutaneous
spreading of the formulation. The potentially smaller surface area generated minimizes
drug contact with the aqueous environment, contributing to a decrease in burst release.
In the time-period following the burst (days 3-7), rivastigmine plasma concentrations
were maintained at higher levels in rats having received the 10% SAM implant
$2
(7-16 ng/g blood) compared to those having received ou or 5% SAM formulations
(6-9 ng/g blood). Following the burst phase, it is thought that drug release is mostly
driven by implant degradation by subcutaneous esterases and lipases [29-3 1], a process
that may be affected by gel density. The question of enzymatic degradation will be
further addressed in future studies.
The only other documented pharmacokinetic study involving the sustained release of
rivastigmine was conducted in minipigs and demonstrated release of the ChEI from a
dermal patch for up to 72 h, with bioavailability values 20-40 times higher than for oral
administration, for which the authors reported only 0.5% bioavailability [16]. Curiously
enough, despite the advantages of sustained dosing regimens, no further studies were
reported in the literature. The present work highlights the possibility of using L-alanine
based oleogels in the sustained release of rivastigmine for up to 11 days, demonstrating
their potential use as in situ-forming implants for AD treatment. Future work will focus
on optimizing the pharmacokinetic behaviour of these implants in the release of
rivastigmine, notably by investigating release mechanisrns involved and exploring the
use of novel amino-acid-derived organogelators.
$3
5. Conclusion
Ibis study tested the sustained rivastigmine release from SAM oleogels.
Physicochemical characterization contributed to the understanding of the effect of
rivastigmine addition on intermolecular interactions within the gel. In vitro and
pharmacokinetic experiments demonstrated the feasibility of using SAM oleogels for the
sustained delivery of rivastigmine at therapeutic levels, and this for up to 11 days after
subcutaneous injection to rats. Compared to the current once-a-day oral administration
of rivastigmine, such a simplified dosing regimen has the potential to alleviate caregiver
responsibilities as well as treatment-related adverse effects caused by high variations in
plasma drug concentration.
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CHAPTER 5
Resuits and discussion
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In situ-forming SAM oleogels were prepared for the subcutaneous administration of
rivastigmine, with the goal of providing a sustained release of the cholinesterase
inhibitor. Gel formation is known to occur upon the self-assembly of SAM gelator
molecules into fibers, stabilized by intermolecular hydrogen-bonding and van der Waals
interactions [1,2]. The libers grow to the extent of overlap and form a sample-spanning
matrix that immobilizes the ou phase by surface tension. The system’s physicochemical
characteristics were investigated to obtain further insight into gel behaviour in response
to temperature, drug-loading, and enantiomeric purity.
Texture profile analysis (Appendix 1) was conducted on drug-free oleogels to test the
relationship between gelator concentration and drug strength. This technique consisted in
introducing a probe into the gel sample, optimized in width and height to avoid wall
effects, and measuring the force needed for penetration to a specified depth. This
experiment provided the hardness of the gel (in Newtons, N), which equals to the peak
force of the first penetration. As expected from previous investigations of fatty acid
derived alanine organogels [1,2], gel strength increased with organogelator concentration
(figure 1).
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Figure 1: Average hardness of oleogels varying in SAM concentration, obtained by
texture profile analysis (Mean + SD, n = 3).
These figures are lower than hardness values typically obtained for hydrogels, which
generally vary between 1 [3] and 25 N [4]. However, a compromise in SAM gel hardness
is needed to allow comfortable injection through conventional needles, while providing
sufficient cohesiveness of the formulation once injected, to avoid excessive spreading.
The in vivo study further highlighted the effect of varying release kinetics in terms of
gelator concentration (Chapter 4, Figure 6).
As discussed in chapter 3, the presence of stereogenic centers within the gelling molecule
can induce supramolecular chirality in gel fibers [5-9], therefore having a great effect on
overall gel characteristics. These studies have shown chirality to have a synergistic effect
on gelation; pure enantiomers often exhibit superior gelling abilities to their
corresponding racemate [5]. lndeed, this general trend has been found to apply to SAM
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oleogels, which exhibit significantly higher sol-gel transition temperatures when used as
pure enantiomers, as opposed to a racemic mixture (Figure 2). Meanwhile. no differences
in transition temperatures were detected between L- and D-SAM
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figure 2: Gelator chirality effect showing a decrease in DSC-determined sol-gel (white
bars) and gel-sol (solid bars) transitions in racernic organogels (D/L-SAM) with respect
to enantiomericatly-pure L- and D-SAM. (Mean, n 2).
These results have been confirmed by IR spectroscopy experiments that compared the
extent of intermolecular hydrogen-bonding as a ftmnction of temperature in
enantiomericatly pure (L-SAM) and racemic (D/L-SAM) oleogels. Using the procedure
outlined in Chapter 4, the band ratio of hydrogen-bonded (649 cm’) and free
(1685 cm1) amide carbonyl groups was plotted against temperature (figure 3).
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Figure 3: FTIR analysis showing the proportion offree amide bonds in drug-free gels, as
determined from the band intensity ratio of amide I peaks at 1685 and 164$ cm1
(I168ç/I1648), as a function of temperature for gels prepared from 10% w/w
enantiomerically pure L-SAM (.) and racemic D/L-SAM (o). respectively. (Mean + SD,
n3)
Ihe resuits obtained, indicated a slight decrease in transition temperature in the case of
racemic gels, corroborating with DSC data (Figure 2). The effect of chirality was tested
tested in vivo, to detect possible changes in the degradation rate of between L- and D
SAM oleogel implants, following the hypothesis that degradation of the gelator derived
from the non-biological D-amino acid woutd be slower [10]. However. no detectable
changes in remaining implant size were detected afier 2- and 5-week time-points (data
flot shown).
Investigations were pursued using organogels prepared with L-SAM (?5%), in an effort
to test the effect of drug loading on gel properties. DSC and FTIR resuits (Chapter 4,
Table I) indicated a weakening of the oleogel structure by the incorporation of 4% w/w
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dissoived drug, as proven by decreasing gel-sol transition temperatures. On the other
hand, the dispersed RHT sait did flot alter gel properties at the same concentration.
Following these physicochemical investigations, in vitro release experiments were
conducted using these oleogels to obtain information on burst release (Chapter 4, Figure
5). NMP was added to gel formulations to partially disrupt getator interactions and to
facilitate injection. Once injected. the solvent was expected to quickly diffuse out of the
formulation, potentially solubilizing drug molecules on its way, thereby increasing burst
release. Nevertheless. no significant difference in burst was noticed between formulations
with and without NMP. When comparing the two drug incorporation methods,
organogels containing dispersed rivastigmine were found to have the lowest burst (<15%
in the first day). Based on these promising results, these gels were chosen for further in
vivo investigation. The pharmacokinetic study conducted on rats dernonstrated a
sustained rivastigmine release within therapeutic range (1 — 400 ng/mL) for up to 11
days. with peak plasma levels well below the toxic threshold and up to five times lower
than for control formulation (Chapter 4, Figure 6).
Since rivastigmine is mostly degraded by the liver, hepatic toxicity was also investigated.
Histological examination of alI treated and 2 untreated control rats did not reveai any
significant ahnormalities (data not shown). Although there was a slight degree of
congestion of the sinusoids, as well as some isolated clusters of infiammatory cells, these
incidentai changes were minor and feit to be of no significance since they were present
both in treated and control animals. Also of note, there was no evidence of bile retention,
active inflammation, widening of the portal tracts or any degree of fibrosis in the
92
animais. This study demonstrates that no toxicity is incurred to the Ïiver by the prolonged
and sustained exposure to rivastigmine.
Overail this project succeeded in estabiishing SAM gels to be a promising option for a
sustained-release formuiation in the treatment of AD.
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CHAPTER 6
Conclusions and outlook
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The eventual use of an SAM organogel as a sustained-release formulation for
rivastigmine is attractive in terms of the simplified dosing schedule it would permit. This
thesis outlined the investigation of the formulation’s physicochemical properties as well
as its in vitro and in vitro release kinetics.
It was determined that the incorporation of the dispersed RHT did flot alter gel properties
up to concentrations of at least 4%, whule the dissolution of RB caused a decrease in gel
transition temperatures at these same concentrations, as concluded from transition
temperatures obtained by DSC and IR investigations. In vitro release profiles allowed to
measure the relative burst effects of different formulations varying in SAM and NMP
content, as well as in the drug incorporation method (dispersed RHT versus dissolved
RB). The loading of oleogels with dispersed RHT permitted a substantial lowering of the
burst release compared to RB-loaded oleogels (10 versus 70% of total rivastigmine
released within the first 12h, respectively). Drawing on these results, a pharmacokinetic
study was conducted in rats, to compare release profiles from organogels varying in SAM
content and containing dispersed RHT. This experiment demonstrated the feasibility of
using SAM oleogels for the sustained delivery of rivastigmine at therapeutic levels, and
this for up to 11 days after subcutaneous injection. Compared to the current once-a-day
oral administration of rivastigmine such a simplified dosing regimen represents an
attractive alternative. Furthermore, the sustained release formulation could possibly
reduce treatment-related adverse effects caused by high variations in plasma drug
concentration.
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The promising resuits obtained as part of this project warrant additional optimisation of
the sustained-release duration and a further decrease in burst. This would allow the
administration of higher doses while prolonging the release period. An interesting avenue
currently investigated is the use of gelators using other amino acids, notably a C20-
dcrivatized tyrosine molecule capable of gelling the ou phase at concentrations as low as
1%. Also, while the use of rivastigmine as a model drug was interesting as a proof of
concept, having allowed incorporation of both hydrophilic and hydrophobic forms of the
compound, the drug’s efficacy in disease management is known to be modest.
Consequently, future studies could focus on the incorporation of newer AD drugs with
potentially better efficacy profiles. Such resuits would move the formulation doser to
eventual usage.
APPENDIX
Metliodology
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Texture profile analysis
The gel samples used in the analysis were rnoulded in aluminum foi! which was
subsequentiy removed to avoid wall-effects. TPA analysis was conducted on a TA.XT2i
texture ana!yzer (Texture Technologies, Hami!ton, MA), using a 1 rnm/s pre-test
penetration speed, and a 0.1 mm/s test and post-test penetration speed. The insertion
depth was set to 2 mm and the trigger force to 0.0 10 N.
Histology
For a histo!ogy study conducted to assess potential !iver toxicity resu!ting from sustained
exposure to rivastigmine, the whole livers of ail treated and two untreated contro! rats
were collected. Part of each organ was fixed with 10% neutral-buffered fonrialin. The
tissue sections were processed and embedded in paraffin and glass siides with 4 tm
tissue sections were prepared using a Leica 2155 microtone (Leica Microsystems Inc.,
Richmond Hill, ON, Canada). S!ides of each liver were stained according to a
hematoxylin-phioxin-safran (HP S) standard procedure [31.
